A Phase 3 interventional study of Vosoritide and Placebo in Hypochondroplasia, sponsored by BioMarin Pharmaceutical. Completed at 23 sites in 9 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by BioMarin Pharmaceutical · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing vosoritide in Dwarfism — 1 open to participants now, 6 under way, 1 of them phase 3. vosoritide · Dwarfism.
Among the 11 studies testing vosoritide in Dwarfism, this one is the 3rd largest by enrollment, is one of 3 that started in 2024, is one of 3 in phase 3, and was the 10th registered.
99 studies on the registry are indexed under Dwarfism; 12 are open to participants now.
Browse Dwarfism studies →1 of the 11 studies testing vosoritide in Dwarfism is open now, in 1 country. Recruiting first, the newest first:
Roopa Kanakatti Shankar, MBBS, MS · Sites in United States
Ages 3–11 · Women only
By country, each count listing its studies:
vosoritide: first FDA approval 2021 (VOXZOGO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 7 Dwarfism studies recruiting now, 1 sets no upper age limit and 5 stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2024.
This study's enrollment of 81 is above the median of 60 across 66 interventional studies indexed under Dwarfism.
Median enrollment 56 across the 11 interventional studies. Of the 5 that completed or were terminated, 3 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 11 have an industry lead sponsor. The 3 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
10 studies in Dwarfism by BioMarin Pharmaceutical: none open now, 4 under way, 1 of them phase 3. Of 6 finished, 3 (50%) have results posted.
Among the 10 studies in Dwarfism by BioMarin Pharmaceutical, this one is one of 2 that started in 2024, is one of 3 in phase 3, and was the 9th registered.
BioMarin Pharmaceutical’s Dwarfism studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing vosoritide in Dwarfism, from their registry updates:
Among BioMarin Pharmaceutical’s 10 in Dwarfism:
This tab as a report to print or save as PDF → With an account.
The intent and design of this Phase 3 study is to assess vosoritide as a therapeutic option for the treatment of children with hypochondroplasia (HCH).
This is a Phase 3 randomized, stratified, placebo-controlled, double-blind multicenter study to evaluate the effect of 52 weeks of daily vosoritide administration on annualized growth velocity (AGV) in participants with HCH. Eligible participants with documented HCH confirmed by genetic testing will roll over from Study 111-902 and enter the 111-303 study. Participants will be randomly assigned to one of two treatment groups: Placebo or Vosoritide. The route of administration is subcutaneous injection, and the frequency of administration is daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vosoritide
Drug: Placebo
Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
Also known as: Modified recombinant human C-type natriuretic peptide
Subcutaneous injection of recommended dose of placebo
Change from baseline in annualized growth velocity (AGV) at Week 52 versus placebo
Time frame: At week 52
Change from baseline in standing height at Week 52 versus placebo
Time frame: At week 52
Change from baseline in height Z-score at Week 52 versus placebo
Time frame: At week 52
Plan to share: No
Ran from Jun 2024 to primary completion in Apr 2026, 22 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2026 → Apr 2026 and completion Aug 2026 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vosoritide